CellSource Co

CellSource Co Gross Profit

The Gross Profit of CellSource Co (4880.T) as of Oct 27, 2026 is 2.09 B JPY. In the previous year, Gross Profit was 2.36 B JPY — a change of -11.64% (lower).

Gross Profit

2.09 BJPY

YoY

-11.64%

Last updated:

Gross Profit of CellSource Co is 2025 2.09 B JPY. Gross Profit of CellSource Co was 2024 2.36 B JPY. It decreases by -11.64% lower compared to the previous year.

The CellSource Co Gross Profit history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Profit
Date
Gross Profit
Jan 1, 2018
873.11 M JPY
Jan 1, 2019
1.15 B JPY
Jan 1, 2020
1.25 B JPY
Jan 1, 2021
2.06 B JPY
Jan 1, 2022
3.05 B JPY
Jan 1, 2023
3.16 B JPY
Jan 1, 2024
2.36 B JPY
Jan 1, 2025
2.09 B JPY
The CellSource Co Gross Profit history
YEARGross ProfitYoY
2.09 BJPY-11.64%
2.36 BJPY-25.23%
3.16 BJPY+3.55%
3.05 BJPY+47.93%
2.06 BJPY+64.89%
1.25 BJPY+9.07%
1.15 BJPY+31.35%
873.11 MJPY+191.11%
299.93 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CellSource Co Revenue

CellSource Co Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2022
4.27 B JPY
1.57 B JPY
1.02 B JPY
Jan 1, 2023
4.47 B JPY
1.26 B JPY
923.14 M JPY
Jan 1, 2024
4.35 B JPY
130.49 M JPY
237.94 M JPY
Jan 1, 2025
3.71 B JPY
166.71 M JPY
10.66 M JPY
Jan 1, 2026 (e)
3.37 B JPY
-98.45 M JPY
-99.15 M JPY
Jan 1, 2027 (e)
3.50 B JPY
101.75 M JPY
79.32 M JPY
Jan 1, 2028 (e)
3.90 B JPY
305.72 M JPY
239.94 M JPY
Jan 1, 2029 (e)
6.07 B JPY
1.28 B JPY
0.00 JPY

CellSource Co Margins

CellSource Co stock margins

The CellSource Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of CellSource Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for CellSource Co.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2022
71.39 %
36.76 %
23.82 %
Jan 1, 2023
70.69 %
28.24 %
20.65 %
Jan 1, 2024
54.26 %
3.00 %
5.47 %
Jan 1, 2025
56.26 %
4.49 %
0.29 %
Jan 1, 2026 (e)
56.26 %
-2.92 %
-2.94 %
Jan 1, 2027 (e)
56.26 %
2.91 %
2.27 %
Jan 1, 2028 (e)
56.26 %
7.84 %
6.15 %
Jan 1, 2029 (e)
56.26 %
21.06 %
0.00 %

CellSource Co Stock analysis

What does CellSource Co do? CellSource Co., Ltd. generates revenue through its Regenerative Medicine Related business segment, which provides contracted services for processing tissues and cells from fat and blood to medical institutions, along with support services for regenerative medicine laws and regulations related to safety assurance. The company also sells medical equipment within this segment. The Consumer business segment focuses on selling cosmetics and facial products directly to general consumers. Both segments operate under the company's brand without additional brand names mentioned in the description. The Regenerative Medicine Related business segment targets medical institutions and regulatory compliance support for regenerative medicine safety, while the Consumer business segment serves general consumers seeking cosmetics and facial care products. The company's products include processed tissue and cell services, regulatory support, medical equipment, and consumer skincare items, all sold under the CellSource brand. CellSource Co., Ltd. employs 109 full-time employees to manage its two business segments, with the Regenerative Medicine Related segment handling medical services and equipment sales, and the Consumer segment focusing on direct-to-consumer product sales. The company's revenue streams are derived from these two distinct operational areas without any additional external partnerships or third-party brands. CellSource Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CellSource Co stock

Gross Profit of CellSource Co is 2.09 B JPY in 2025.

Gross Profit of CellSource Co changed from 2.36 B JPY to 2.09 B JPY, representing a -11.64% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Profit CellSource Co since 2006 – with annual values, charts, and detailed analysis.

Gross Profit is the revenue remaining after deducting the cost of goods sold. It shows how efficiently a company uses its resources to produce goods or services.

Gross Profit's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Gross Profit's CellSource Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — CellSource Co

All Key Metrics — CellSource Co